SEC Form 4 · accession 0000886163-17-000119
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Oct 13, 2017
Accepted (ET)
Oct 17, 2017 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 13, 2017 | M | 11,384 | $21.92 | A | 150,555 | D | |
| Common StockF1 | Oct 13, 2017 | F | 1,744 | $143.04 | D | 148,811 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $21.92 | Oct 13, 2017 | M | 11,384 | D | — | Feb 15, 2023 | Common Stock | 11,384 | 0 | D |
Explanation of responses
- F1Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.